The chronic obstructive pulmonary disease (COPD) market across the seven major markets (7MM: US, France, Germany, Italy, ...

Chronic lower respiratory diseases, namely, asthma and chronic obstructive pulmonary disease , are the fifth-leading cause of ...

Sanofi reports amlitelimab improved lung function in asthma, with new phase 3 trials planned across its respiratory pipeline.

Treatments for COPD, psoriasis, and neuroendocrine tumors, as well as a next-generation COVID-19 vaccine are under review.

Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD: Paris Wednesday, April 16, 2025, 10:00 Hrs [IST] Sanofi shared new pro ...

RespirAI Medical, a digital health startup, is expanding its clinical activity to advance innovation in treating chronic respiratory diseases.

Long-term ICS use in COPD increases risks of severe health conditions like Type 2 diabetes and fractures. Read more!

Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

Common symptoms of pneumonia include a persistent cough, difficulty breathing, high fever, chest pain, body aches, extreme tiredness, and a loss of appetite, according to the NHS website.